Quintrio
Home

Stock overview

QIAGEN N.V.

QGEN

Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between life sciences and molecular diagnostics applications. Qiagen generates nearly 90% of its revenue from consumables, with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by Europe, the Middle East, and Africa (33%) and Asia-Pacific (15%).

Last trade $49.74
Day change -$0.07 (-0.14%)
Day range $49.68 – $49.87
Volume 1,651,847
Market cap $10.29B

Open XNYS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for QGEN.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for QGEN.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Cell Lysis / Cell Fractionation - Global Strategic Business Report 2026: Capture the $4.5 Billion Market by 2032 | Features Competitive Intelligence on Thermo Fisher, Beckman Coulter, Bio-Rad, Qiagen and Merck

The global cell lysis and cell fractionation market is projected to grow from $2.8 billion in 2025 to $4.5 billion by 2032, expanding at a 7% CAGR. Growth is driven by advances in biotechnology, personalized medicine, proteomics, genomics research, and biopharmaceutical development. Emerging technologies including automation, microfluidics, AI/ML integration, and single-cell analysis capabilities are reshaping the market landscape.

GlobeNewswire Inc.

AI in Drug Discovery Market to Reach USD 15,536.2 Million by 2033 at 25.1% CAGR | Coherent Market Insights

The global AI in drug discovery market is projected to grow from USD 3,240.0 million in 2026 to USD 15,536.2 million by 2033, with a CAGR of 25.1%. Growth is driven by increasing pharmaceutical investments in AI infrastructure, machine learning adoption, and collaborations between pharma companies and AI providers. North America leads with 51.6% market share, while Asia Pacific shows the fastest growth at 27.2% CAGR. Key trends include generative AI for molecule design, multimodal AI for biological data analysis, and growing focus on AI model validation.

Zacks Investment Research

Compared to Estimates, Qiagen (QGEN) Q3 Earnings: A Look at Key Metrics

Qiagen reported Q3 2026 revenue of $547.87 million, up 2.9% year-over-year, beating consensus estimates by 1.56%. EPS of $0.65 exceeded expectations of $0.63 by 3.18%. Key product segments showed mixed results, with Genomics/NGS and Sample Technologies performing well, while PCR/Nucleic acid amplification and Diagnostic solutions-Other declined. The stock has gained 10.4% over the past month and holds a Zacks Rank #2 (Buy) rating.

Zacks Investment Research

Do Options Traders Know Something About Qiagen Stock We Don't?

Qiagen N.V. (QGEN) is attracting investor attention due to high implied volatility in its December 2026 $55 put options, suggesting traders expect significant price movement. Despite the options market activity, the company maintains a Zacks Rank #2 (Buy) rating with modest analyst estimate increases for the current quarter.

GlobeNewswire Inc.

Thailand Next Generation Sequencing (NGS) Market Size, Share, Trends, and Forecast - 2026 to 2036 | Precision Medicine Drives 12.7% CAGR and a $305.21 Million Opportunity

Thailand's NGS market is projected to reach $305.21 million by 2036, growing at a 12.7% CAGR from $92.03 million in 2026. Growth is driven by the Genomics Thailand national precision medicine initiative, rising clinical adoption in oncology and rare diseases, expanded reimbursement under the Universal Coverage Scheme, and increasing demand for outsourced sequencing services. Commercial sequencing services and clinical applications in oncology are expected to be the fastest-growing segments.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Jul 7, 2026$0.35Jul 14, 2026recurring
Jan 8, 2026$2.29—unknown
Jul 2, 2025$0.25Jul 10, 2025recurring
Jan 29, 2025$1.26—unknown
Jan 25, 2017$1.1028—unknown

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Jan 29, 202535-for-36reverse split
Jan 30, 202424.25-for-25reverse split
Jan 25, 201726-for-27reverse split